Portal de investigación
- Inicio
- Proyectos y Estudios
- ESTUDIO DE FASES I/III INTEGRADAS, ALEATORIZADO, EN DOBLE CIEGO Y MULTICÉNTRICO, EN MUJERES POSMENOPÁUSICAS CON OSTEOPOROSIS, COMPARATIVO DE LA FARMACOCINÉTICA, FARMACODINAMIA, EFICACIA, SEGURIDAD E INMUNOGENIA DE GP2411 (PRODUCTO BIOLÓGICO PROPUESTO SIMILAR AL DENOSUMAB) FRENTE A PROLIA® (PRODUCTO AUTORIZADO EN LA UE).
ESTUDIO DE FASES I/III INTEGRADAS, ALEATORIZADO, EN DOBLE CIEGO Y MULTICÉNTRICO, EN MUJERES POSMENOPÁUSICAS CON OSTEOPOROSIS, COMPARATIVO DE LA FARMACOCINÉTICA, FARMACODINAMIA, EFICACIA, SEGURIDAD E INMUNOGENIA DE GP2411 (PRODUCTO BIOLÓGICO PROPUESTO SIMILAR AL DENOSUMAB) FRENTE A PROLIA® (PRODUCTO AUTORIZADO EN LA UE).
Datos básicos
- Código:
- CGP24112301
- Protocolo:
- CGP24112301
- EUDRACT:
- 2018-003523-11
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2020
- Año de finalización:
- 2022
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry
Estrada-Alarcon, Paula V.; (...); Blanco, Ricardo
Meeting Abstract. 2023
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.
Fernández-Díaz C; (...); Blanco R
Article. 10.1093/rheumatology/keaa621. 2020
-
-
PlumX Metrics
- Citations
- Citation Indexes: 85
- Policy Citations: 2
- Captures
- Readers: 82
- Mentions
- News Mentions: 1
ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS
Fernandez-Diaz, C; (...); Blanco, R
Meeting Abstract. 10.1136/annrheumdis-2021-eular.892. 2021
ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS.
Fernandez-Diaz, Carlos; (...); Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumat
Article. 10.1093/rheumatology/keab317. 2022
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients
Fernandez-Diaz, C.; (...); Blanco, Ricardo
Meeting Abstract. 2019
ABATACEPT IN USUAL AND IN NON-SPECIFIC INTERSTITIAL PNEUMONIA ASSOCIATED TO RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 190 PATIENTS
Atienza-Mateo, B; (...); Blanco, R
Meeting Abstract. 10.1136/annrheumdis-2021-eular.711. 2021
Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients
Atienza-Mateo, Belen; (...); Blanco, Ricardo
Meeting Abstract. 2021
Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis
Atienza-Mateo B; (...); Blanco R
Article. 10.1016/j.ejim.2023.08.025. 2024
Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients
Fernandez-Diaz, C; (...); Blanco, R
Meeting Abstract. 2020
ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis
De Miguel, Eugenio; (...); Blanco-Alonso, Ricardo
Meeting Abstract. 2024
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
After JAK Inhibitor Failure, "Switching" or "Cycling"?
Munoz Martinez, Pablo Francisco; (...); Roman Ivorra, Jose Andres
Meeting Abstract. 2023
AFTER JAK INHIBITOR FAILURE, 'SWITCHING' OR 'CYCLING'?
Munoz Martinez, P.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4124. 2023
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
ANNALYSIS OF PRO-INFLAMMATORY BIOMARKERS IN A POLYMYALGIA RHEUMATICA COHORT DURING THE ACUTE ONSET OF THE DISEASE
Sanjuan, FMO; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2021-eular.3114. 2021
ANTIMALARIAL DRUGS AND ELECTROCARDIOGRAPHIC ALTERATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.
Barcena, C. Riesco; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.2847. 2022
Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behcet's Disease: National Multicenter Study of 51 Cases
Atienza-Mateo, Belen; (...); Blanco, Ricardo
Meeting Abstract. 2019
APREMILAST IN MONOTHERAPY OR COMBINED IN NON-ULCER MANIFESTATIONS OF BEHCET'S DISEASE. NATIONAL MULTICENTER STUDY OF 34 REFRACTORY CASES OF CLINICAL PRACTICE
Morant, AH; (...); Blanco, R.
Meeting Abstract. 10.1136/annrheumdis-2020-eular.4720. 2020
Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice.
Atienza-Mateo B; (...); Blanco R
Article. 2020
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Martinez Calabuig, Pablo; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
Autologous stem cell transplantation in systemic sclerosis: 4 cases.
de la Rubia Navarro, Marta, Leal Rodriguez, Samuel, Roman Ivorra, Jose Andres
Article. 10.1016/j.reumae.2025.501810. 2025
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
BASELINE PROFILE OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS ON TREATMENT WITH BELIMUMAB OF A SPANISH MULTICENTER COHORT
Altabas Gonzalez, I.; (...); Rua-Figueroa, I.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.3003. 2023
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Cardiovascular Risk Assessment with Carotid Ultrasonography in Addition to the Traditional Cardiovascular Risk Factor in Rheumatoid Arthritis: A Case Control Study
Mazario, RG; (...); Ivorra, JAR
Meeting Abstract. 2020
CARDIOVASCULAR RISK ASSESSMENT WITH CAROTID ULTRASONOGRAPHY IN ADDITION TO THE TRADITIONAL CARDIOVASCULAR RISK FACTORS IN RHEUMATOID ARTHRITIS PATIENTS: A CASE CONTROL STUDY
Mazario, RG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.6420. 2020
Cardiovascular risk assessment with carotid ultrasound in rheumatoid arthritis.
González Mazarío R; (...); Román Ivorra JA
Article. 10.1016/j.medcli.2022.01.017. 2022
CLINICAL AND SEROLOGICAL EVOLUTION OF RHEUMATIC PATIENTS INFECTED BY SARS-COV-2
Navarro, M. De la Rubia; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.4559. 2022
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical trials: their contribution to the efficiency of the clinical management of rheumatoid arthritis.
Escandell CPA, Ivorra JAR
Article. 10.7573/dic.212612. 2019
CLINICAL VARIABILITY IN PATIENTS DIAGNOSED OF JUVENILE IDIOPATHIC ARTHRITIS WITH POSITIVE AND NEGATIVE ANTINUCLEAR ANTIBODIES (ANA)
Torrat Noves, A. M.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.5203. 2023
COMORBIDITY CLUSTERS AND THEIR RELATIONSHIP WITH SEVERITY AND OUTCOMES OF THE INDEX DISEASES, IN A LARGE MULTICENTER SYSTEMIC LUPUS ERYTHEMATOSUS COHORT (RELESSER REGISTER)
Rua-Figueroa, I.; (...); Pego-Reigosa, J. M.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4168. 2023
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases
Perales, CP; (...); Ivorra, JAR
Meeting Abstract. 2020
CONCORDANCE BETWEEN THE QUANTIFERON-TB GOLD IN-TUBE AND TUBERCULIN TEST FOR THE DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH RHEUMATIC DISEASES
Perales, CP; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2021-eular.3157. 2021
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
COVID-19 AND JAKI: ANALYSIS AFTER THREE-YEAR PANDEMIC AT A SPANISH TERTIARY CARE HOSPITAL
Munoz Martinez, P.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4263. 2023
Cranial and extracranial giant cell arteritis do not exhibit differences in the IL6 -174 G/C gene polymorphism.
Genre, F.; (...); Gonzalez-Gay, M. A.
Article. 10.55563/clinexprheumatol/cbjnmo. 2023
Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association
Prieto-Pena, D; (...); Gonzalez-Gay, MA
Article. 10.1016/j.semarthrit.2020.07.004. 2020
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
CT GUIDED NEEDLE BIOPSY IN VERTEBRAL OSTEOMYELITIS: RELIABILITY ANALYSIS AND STUDY OF WHICH FACTORS COULD INFLUENCE ON THE RESULT
Fragio-Gil, J. J.; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.6383. 2020
CT-Guided Needle Biopsy in Vertebral Osteomyelitis: Study of Factors That Could Influence in Culture Yield.
Fragío Gil JJ; (...); Román Ivorra JA
Article. 10.1016/j.reumae.2020.08.007. 2022
CT-Guided Needle Biopsy in Vertebral Osteomyelitis: Study of Factors That Could Influence in Culture Yield
Fragio Gil, Jorge Juan; (...); Roman Ivorra, Jose Andres
Article. 10.1016/j.reuma.2020.08.002. 2022
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Decreased DNA hydroxymethylation and increased DNA demethylation are associated with high antioxidant response in systemic lupus erythematosus patients.
Fragío Gil JJ; (...); Román Ivorra JA
Case Reports. 10.1016/j.medcli.2020.10.023. 2021
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry
De Miguel, Eugenio; (...); Blanco, Ricardo
Meeting Abstract. 2021
Do antiTNF or Ustekinumab trough levels correlate with joint extraintestinal manifestations activity in Inflammatory bowel disease patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2024
Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2023
Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases.
de la Rubia Navarro, Marta; (...); Roman Ivorra, Jose Andres
Article. 10.1016/j.medcli.2022.05.003. 2022
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effect of different schemes of androgen deprivation therapy on bone mass density in prostate cancer patients.
Arevalo Ruales, Karla; (...); Roman Ivorra, Jose Andres
Article. 10.1016/j.medcli.2022.03.026. 2023
EFFECTIVENESS OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS OF A MULTICENTER SPANISH COHORT
Altabas Gonzalez, I.; (...); Rua-Figueroa, I.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.3482. 2023
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
Sanchez-Bilbao, Lara; (...); Blanco, Ricardo
Meeting Abstract. 2021
Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice
Sanchez-Bilbao, Lara; (...); Blanco, Ricardo
Meeting Abstract. 2021
EFFICACY AND SAFETY OF APREMILAST IN BEHCET DISEASE PATIENTS
Bernabeu, EV; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.5330. 2020
EFFICACY AND SAFETY OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS: DATA FROM REAL-WORLD
Mazario, RG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.6321. 2020
Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution
Calderon-Goercke, Monica; (...); Blanco, Ricardo
Meeting Abstract. 2019
Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus
Blanco, Ricardo; (...); Alvaro-Gracias, Jose Maria
Meeting Abstract. 2023
EPIDEMIOLOGY, DIAGNOSIS AND CLINICAL CHARACTERISTICS OF GIANT CELL ARTERITIS IN PATIENTS INCLUDED IN THE ARTESER MULTICENTER STUDY
Sanchez-Costa, J. T.; (...); Blanco, R.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.1313. 2022
Erratum corrige: "Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study". J.L. Pablos et al.
Pablos JL; (...); Rivero N
Correction. 2020
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
EXPERIENCE IN REAL-WORLD CONDITIONS OF THE EFFECTIVENESS OFTHEVACCINE AGAINST HERPES ZOSTER
Mas Sanchez, L.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4258. 2023
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Genotype FBN1/Phenotype relationship in a cohort of patients with Marfan syndrome.
Hernándiz A; (...); Sepúlveda P
Article. 10.1111/cge.13879. 2020
Giant Cell Arteritis Subtypes: Data from the ARTESER Registry
De Miguel, Eugenio; (...); Blanco, Ricardo
Meeting Abstract. 2021
Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Munoz Martinez, Pablo; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
HEALTH-RELATED QUALITY OF LIFE MEASURES IN SPONDYLOARTHROPATY PATIENTS UNDER BIOLOGICAL THERAPIES IN REAL LIFE
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2021-eular.2282. 2021
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab.
Riesco-Bárcena C; (...); Román-Ivorra J
Article. 10.1016/j.medcli.2024.07.020. 2024
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
IMPACT OF GENDER IN JAK INHIBITORS PRESCRIPTION: ANALYSIS FROM A SINGLE CENTER COHORT
Garcia, E. Grau; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.3917. 2022
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register.
Fernandez-Lozano, Delia; (...); Blanco, Ricardo
Article. 10.1136/rmdopen-2023-003824. 2024
Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study
Sanchez-Costa, Jesus T.; (...); Blanco, Ricardo
Meeting Abstract. 2021
Incidence of Hyperparathyroidism in Patients with Osteoporosis Treated with Zoledronic Acid or Denosumab
Riesco Barcena, Carmen; (...); Roman Ivorra, Jose Andres
Meeting Abstract. 2023
Increase of IL10 and IFNa2 Are Associated to Clinical Activity in Systemic Lupus Erythematous Patients
Grau Garcia, Elena; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
De Miguel, Eugenio; (...); Blanco, Ricardo
Article. 10.1136/rmdopen-2022-002507. 2022
Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register (vol 8, e002507, 2022)
De Miguel, Eugenio; (...); Blanco, Ricardo
Correction. 10.1136/rmdopen-2022-002507corr1. 2023
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments
Altabas Gonzalez, Irene; (...); Rua-Figueroa, Inigo
Meeting Abstract. 2023
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
JAK inhibitors in combination with anti-TNF drugs on difficult-to-treat chronic polyarthritis: a case series.
Leal S; (...); Román-Ivorra JA
Letter. 10.55563/clinexprheumatol/4ao14k. 2024
LUPUS NEPHRITIS RESPONSE IN TERMS OF KIDNEY FUNCTION, URINE SEDIMENT AND SEROLOGICAL ACTIVITY AFTER SUBCUTANEOUS BELIMUMAB TREATMENT
De la Rubia Navarro, M.; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.2944. 2022
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
Molina-Collada, Juan; (...); Blanco-Alonso, Ricardo
Meeting Abstract. 2024
Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry
Molina-Collada, Juan; (...); ARTESER Project Collaborative Grp, Clara
Article. 10.1186/s13075-024-03468-6. 2025
Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus
Rua-Figueroa, Inigo; (...); Calvo Alen, Jaime
Article. 10.1016/j.reuma.2024.03.005. 2024
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
Musculoskeletal Manifestations in Patients Diagnosed with Marfan Syndrome
Mas Sanchez, Laura; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.
Zafra J; (...); Barragán I
Article. 10.3390/ijms25084533. 2024
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients
Calderon-Goercke, Monica; (...); Blanco, Ricardo
Meeting Abstract. 2019
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Prevalence and clinical characteristics of patients with rheumatoid arthritis with interstitial lung disease using unstructured healthcare data and machine learning
Román Ivorra JA; (...); Castellanos-Moreira R
Article. 10.1136/rmdopen-2023-003353. 2024
PREVALENCE AND COMORBIDITIES OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN SPAIN: A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORDS USING NATURAL LANGUAGE PROCESSING
Roman Ivorra, J. A.; (...); Lujan Valdes, S.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.5042. 2022
PREVALENCE, DIAGNOSTIC DELAY AND TREATMENT PROFILE OF PATIENTS WITH MONOGENIC AUTOINFLAMMATORY DISEASES IN AN ADULT RHEUMATOLOGY SERVICE OF A TERTIARY HOSPITAL.
Perales, C. Pavez; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.4143. 2022
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
PROFILE OF REAL WORLD AXIAL SPONDYLOARTHRITIS PATIENTS REFRACTORY TO ADVANCED THERAPY
Alcantara Alvarez, I; (...); Roman Ivorra, J. A.
Meeting Abstract. 2024
PROFILE OF REFRACTORY RA PATIENTS FOR TARGETED THERAPIES IN REAL LIFE
Garcia, E. Grau; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2023-eular.4014. 2023
PROSPECTIVE STUDY OF 24 MONTHS OF EVOLUTION OF A COHORT OF PATIENTS WITH RHUPUS
Cordellat, I. Martinez; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.3898. 2022
PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: 10 YEARS EXPERIENCE.
Ortiz-Sanjuan, F.; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.3085. 2022
PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: A NEW TOOL FOR SYSTEMIC SCLEROSIS CLASIFFICATION?
Sanjuan, FMO; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.4423. 2020
REAL LIFE SAFETY AND SURVIVAL OF TARGETED THERAPIES IN ARTHRITIS PATIENTS OVER AGE OF 65
Grau Garcia, E.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.3018. 2023
Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients
Atienza-Mateo, Belen; (...); Blanco, Ricardo
Meeting Abstract. 2023
Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study
Gonzalez Mazario, Roxana; (...); Roman Ivorra, Jose Andres
Article. 10.1016/j.reuma.2021.08.001. 2022
Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study.
González Mazarío R; (...); Román Ivorra JA
Article. 10.1016/j.reumae.2021.08.004. 2022
Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain
Roman Ivorra, Jose A., Llevat, Noelia, Montoro, Maria
Article. 10.5582/ddt.2022.01028. 2022
Red flags for clinical suspicion of eosinophilic granulomatosis with polyangiitis (EGPA).
Solans-Laque, R; (...); Cid, M C
Article. 10.1016/j.ejim.2024.06.008. 2024
Refractory RA Patients for Targeted Therapies in Real Life
Grau Garcia, Elena; (...); Roman Ivorra, Jose Andres
Meeting Abstract. 2023
RESPONSE OF BEHCET'S REFRACTORY ORAL AND/OR GENITAL ULCERS TO APREMILAST IN COMBINATION VS MONOTHERAPY. NATIONAL MULTICENTER STUDY OF 51 CASES OF CLINICAL PRACTICE
Morant, AH; (...); Blanco, R.
Meeting Abstract. 10.1136/annrheumdis-2020-eular.6246. 2020
Rhupus syndrome: Description of 9 cases with special attention to the HLA-DR genotype
Hurtado, Andres Perez; (...); Ivorraa, Jose Andres Roman
Article. 10.1016/j.medcli.2024.09.006. 2025
RITUXIMAB SAFETY AND PERSISTENCE IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES
Perales, CP; (...); Ivorra, JAR
Meeting Abstract. 2020
SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound
Campos Fernandez, Cristina; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
SECONDARY PREVENTION OF VERTEBRAL FRACTURES SUSTAINED EFFICACY OVER TIME
Oller Rodriguez, J. E.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.3312. 2022
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
Serological Evidence of SARS-CoV-2 in Symptomatic Patients Under Biological Treatment in a Rheumatology Service
Perales, CP; (...); Ivorra, JAR
Meeting Abstract. 2020
Sex Differences in Giant Cell Arteritis: Data from the ARTESER Registry
Fernandez-Lozano, Delia; (...); Blanco, Ricardo
Meeting Abstract. 2023
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta
Ramos Castro, Daniel; (...); Roman-Ivorra, Jose A.
Meeting Abstract. 2024
Sustained Drug-Free Remission in Giant Cell Arteritis.
Narvaez, Javier; (...); Blanco, Ricardo
Article. 10.1093/rheumatology/keae644. 2024
Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry
Narvaez-Garcia, Javier; (...); Blanco-Alonso, Ricardo
Meeting Abstract. 2024
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The impact of disease activity on health-related quality of life in patients with systemic lupus erythematosus.
Grau García E; (...); Román Ivorra JA
Article. 10.1016/j.medcli.2022.11.019. 2023
The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis
Prieto-Pena, D; (...); Gonzalez-Gay, MA
Article. 2021
The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis.
Prieto-Peña D; (...); González-Gay MA
Article. 2021
THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS
Rodriguez, JEO; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2020-eular.5019. 2020
The Role of Plasma Calprotectin in Non-infectious Uveitis.
Pascual EV; (...); Ivorra JAR
Article. 10.1080/02713683.2020.1867749. 2021
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients.
Altabás-González I; (...); Rúa-Figueroa I
Article. 10.1093/rheumatology/kead696. 2024
TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS
Prieto-Pena, D; (...); Blanco, R
Meeting Abstract. 10.1136/annrheumdis-2021-eular.1747. 2021
Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
Prieto-Pena, Diana; (...); Blanco, Ricardo
Meeting Abstract. 2021
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice
Calderon-Goercke, M; (...); Blanco, R
Article. 10.1016/j.semarthrit.2019.01.003. 2019
-
-
-
PlumX Metrics
- Citations
- Citation Indexes: 79
- Policy Citations: 2
- Captures
- Readers: 171
- Mentions
- News Mentions: 5
Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice
Calderon-Goercke, M; (...); Blanco, R
Article. 2020
Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice.
Calderón-Goercke M; (...); Blanco R
Article. 2020
Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous
Calderon-Goercke, Monica; (...); Blanco, Ricardo
Meeting Abstract. 2019
Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone
Calderon-Goercke, Monica; (...); Blanco, Ricardo
Meeting Abstract. 2019
TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY
Prieto-Pena, D.; (...); Blanco, R.
Meeting Abstract. 10.1136/annrheumdis-2022-eular.2330. 2022
Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review
Prieto-Pena, Diana; (...); Blanco, Ricardo
Article. 10.1177/1759720X211020917. 2021
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
TRANSITIONAL CARE IN JUVENILE IDIOPATHIC ARTHRITIS: TIMING, PREVALENCE OF SUBTYPES AND TREATMENT PROFILE IN A SPANISH TERTIARY HOSPITAL.
Perales, C. Pavez; (...); Ivorra, J. A. Roman
Meeting Abstract. 10.1136/annrheumdis-2022-eular.4126. 2022
Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
Sanchez-Costa, Jesus T.; (...); Blanco, Ricardo
Meeting Abstract. 2021
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.
Galíndez-Agirregoikoa E; (...); Tofacitinib PsA Clinical Practice Collaborative Group
Article. 10.3899/jrheum.201204. 2021
TREATMENT, ADVERSE EVENTS AND FOLLOW UP IN PATIENTS WITH GIANT CELL ARTERITIS IN THE ARTESER MULTICENTER STUDY
Sanchez-Costa, J. T.; (...); Blanco, R.
Article. 10.1136/annrheumdis-2022-eular.1314. 2022
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
USE OF RITUXIMAB IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY AND DIFFUSE CUTANEOUS INVOLVEMENT. A SERIES OF 15 CASES
Ortiz Sanjuan, F.; (...); Roman Ivorra, J. A.
Meeting Abstract. 10.1136/annrheumdis-2023-eular.2961. 2023
Utility of cytokines CXCL4, CXCL8 and GDF15 as biomarkers in systemic sclerosis.
Oller-Rodriguez, Jose E.; (...); Roman Ivorra, Jose A.
Article. 10.1016/j.medcli.2021.12.006. 2022
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.
Prieto-Pena, D.; (...); Gonzalez-Gay, M. A.
Article. 10.55563/clinexprheumatol/8mku9c. 2022
Vertebral osteomyelitis: Clinical, microbiological and radiological characteristics of 116 patients
Gil, JJF; (...); Ivorra, JAR
Article. 10.1016/j.medcli.2019.12.029. 2020
Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry
Molina-Collada, Juan; (...); Blanco, Ricardo
Meeting Abstract. 2023